# A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL

> **NCT05178836** · PHASE2 · UNKNOWN · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 62 (estimated)

## Conditions studied

- RR DLBCL; PD-1; CD20

## Interventions

- **DRUG:** F520+F007

## Key facts

- **NCT ID:** NCT05178836
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2022-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178836, "A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05178836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*